Department of Dermatology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Cancer Res Commun. 2024 Oct 1;4(10):2756-2765. doi: 10.1158/2767-9764.CRC-24-0297.
Our findings are of interest to readers because they bring new evidence that small-molecule CCR4 antagonists may be an alternative therapeutic strategy to target CCR4+ CTCL cells. They may inhibit CCR4 function but not eradicate cells, so the side effects may be avoided or minimized.
我们的研究结果对读者具有重要意义,因为它们提供了新的证据,表明小分子 CCR4 拮抗剂可能是一种替代治疗策略,用于靶向 CCR4+ CTCL 细胞。它们可能抑制 CCR4 功能但不根除细胞,因此可以避免或最小化副作用。